SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp selloff with no confirmed company news is driving discussion, with traders attributing the move to options expiration, broader biotech weakness, or possible selling pressurenone of which is established as the cause. The decline has intensified debate over SELLASs prolonged quiet period and the pending REGAL trial update: some investors are buying the dip while others are concerned about the lack of communication and uncertain trial timing.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas next-generation Roadster reveal, featuring SpaceX-linked thrusters and aerial stunts, is driving discussion. Traders are split between enthusiasm for the engineering and skepticism that the delayed, low-volume car will add meaningful earnings, with some also speculating the demo signals a TeslaSpaceX merger; many viewed the initial rally as fading.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves heavy debt burden, rising borrowing costs, and ability to finance its AI infrastructure expansion are driving discussion amid a broader selloff in AI and neocloud stocks. Traders are split between viewing the sharp rebound after Nvidia CEO Jensen Huangs reassuring comments as a buying opportunity and treating it as a temporary bounce, with credit and refinancing risks still central to the bearish case.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

The iPhone Duos rapid preorder sellout and extended delivery estimates are driving attention, with some traders viewing them as evidence of strong demand while skeptics argue limited launch inventory and manufacturing constraints may explain the delays. The news has fueled bullish interest, alongside debate over whether the expensive foldable can add meaningful sales or mainly shift demand from other iPhones.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

A broad semiconductor and AI-linked selloff, amplified by weakness in South Korean markets and worries about Chinese memory competition, has pressured SK Hynix. Traders disagree on whether CXMTs progress threatens memory makers soon or is overblown, with some seeing the drop as a buying opportunity and others expecting further declines.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a tech and AI-linked selloff, with traders citing concerns about AI spending and returns alongside elevated inflation and bond yields. The community is divided between expecting more downside and viewing the pullback as oversold, while many describe volatile, choppy trading and rotation out of tech.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, amid concerns about AI spending and profitability, hot inflation and higher rates, has intensified pressure on SOXL; its 3x leverage magnifies the swings. Traders are divided between buying what they see as an oversold dip and warning that the AI trade is unwinding and losses may continue.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAXs sharp selloff is being tied by traders to a circulated TipRanks report claiming an FDA setback in Novavaxs flu/COVID combo trial, though many dispute the report as false or recycled. Some also point to Citis reiterated Sell rating and weakness across vaccine stocks, while accusing trading algorithms of amplifying the decline.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is under pressure amid a broader tech selloff tied to inflation and higher borrowing costs, with lingering concern about its convertible-note financing and potential dilution adding to the debate. Some traders view the financing as low-cost capital that could support buybacks or acquisitions and see the pullback as a buying opportunity, while others fear further downside.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept into a selloff in AI infrastructure and neocloud stocks amid concerns over CoreWeaves debt and whether providers can finance the AI buildout at sustainable costs. Traders are split between buying the pullback, arguing Nebius has a stronger balance sheet than peers, and fearing broader funding risks and an AI-sector downturn.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX  Earnings and earnings call were both GREAT. Ignore the crazy fluctuations which ALWAYS happen in biotech investing and we have a huge war going on in the Middle East effecting the mkts. All you have to do is HODL and get RICH!

FishOn

Perry Smelser

Johann

BeautifulBiosInGreen

cyberInvest

KnysnaNow

Jeremy Richter

Mathew Olz

michael

Big AL

matuli

Peter

Heg Grudson

Bubba

Ulaughing

Dan Storey

StockTwits Web

ImmunityBio Inc

  Earnings and earnings call were both GREAT. Ignore the crazy fluctuations which ALWAYS happen in biotech investing and we have a huge war going on in the Middle East effecting the mkts. All you have to do is HODL and get RICH!

Gordon Gekko

@GordonGekko888 couldn’t agree more. From this price this is going 5x in a year and 10+ x in two. At any point they have more approvals coming in the Middle East. Setting up for treating multiple conditions not just cancer. Big focus on the importance of treating lymphoma which only Anktiva can successfully do with IL15. Patent on this until 2035. They are ahead of BP and Dr Pat knows it, hence him saying “I was just being polite” about BP. Stated he won’t sell that says it all, he knows where this is going. Shorting price action is because BP know it as well. Trying to keep it from growing quickly but it is only a matter of time now.

StockTwits for iOS

 couldn’t agree more. From this price this is going 5x in a year and 10+ x in two. At any point they have more approvals coming in the Middle East. Setting up for treating multiple conditions not just cancer. Big focus on the importance of treating lymphoma which only Anktiva can successfully do with IL15. Patent on this until 2035. They are ahead of BP and Dr Pat knows it, hence him saying “I was just being polite” about BP. Stated he won’t sell that says it all, he knows where this is going. Shorting price action is because BP know it as well. Trying to keep it from growing quickly but it is only a matter of time now.